Literature DB >> 24116940

Expression and purification of recombinant human apolipoprotein A-II in Pichia pastoris.

Manman Su1, Yitian Qi, Mingxing Wang, Weiqin Chang, Shuang Peng, Tianmin Xu, Dingding Wang.   

Abstract

Apolipoprotein A-II (ApoA-II) is the second most abundant protein constituent of high-density lipoprotein (HDL). The physiologic role of ApoA-II is poorly defined. ApoA-II may inhibit lecithin:cholesterol acyltransferase and cholesteryl-ester-transfer protein activities, but may increase the hepatic lipase activity. ApoA-II may also inhibit the hepatic cholesteryl uptake from HDL probably through the scavenger receptor class B type I depending pathway. Interpretation of data from transgenic and knockout mice of genes involved in lipoprotein metabolism has been often complicated as clinical implications because of species difference. So it is important to obtain human ApoA-II for further studies about its functions. In our studies, Pichia pastoris expression system was first used to express a high-level secreted recombinant human ApoA-II (rhApoA-II). We have cloned the cDNA encoding human ApoA-II and achieved its high-level secreting expression with a yield of 65 mg/L of yeast culture and the purification process was effective and easy to handle. The purified rhApoA-II can be used to further study its biological activities.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24116940      PMCID: PMC3804080          DOI: 10.1089/adt.2013.511

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  17 in total

Review 1.  Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein.

Authors:  F Blanco-Vaca; J C Escolà-Gil; J M Martín-Campos; J Julve
Journal:  J Lipid Res       Date:  2001-11       Impact factor: 5.922

2.  Amino acid sequence of human apoLp-Gln-II (apoA-II), an apolipoprotein isolated from the high-density lipoprotein complex.

Authors:  H B Brewer; S E Lux; R Ronan; K M John
Journal:  Proc Natl Acad Sci U S A       Date:  1972-05       Impact factor: 11.205

Review 3.  The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution.

Authors:  W H Li; M Tanimura; C C Luo; S Datta; L Chan
Journal:  J Lipid Res       Date:  1988-03       Impact factor: 5.922

Review 4.  Apolipoproteins of human plasma high density lipoproteins. Biology, biochemistry and clinical significance.

Authors:  A M Scanu; C Edelstein; J I Gordon
Journal:  Clin Physiol Biochem       Date:  1984

5.  Role of individual amino acids of apolipoprotein A-I in the activation of lecithin:cholesterol acyltransferase and in HDL rearrangements.

Authors:  K H Cho; D M Durbin; A Jonas
Journal:  J Lipid Res       Date:  2001-03       Impact factor: 5.922

6.  High yield expression and purification of recombinant human apolipoprotein A-II in Escherichia coli.

Authors:  Loren E Smith; Jun Yang; Leah Goodman; Xinqi Huang; Rong Huang; James Dressman; Jamie Morris; R A Gangani D Silva; W Sean Davidson; Giorgio Cavigiolio
Journal:  J Lipid Res       Date:  2012-05-25       Impact factor: 5.922

7.  ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance.

Authors:  J C Escolà-Gil; J Julve; A Marzal-Casacuberta ; J Ordóñez-Llanos; F González-Sastre; F Blanco-Vaca
Journal:  J Lipid Res       Date:  2001-02       Impact factor: 5.922

8.  Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia.

Authors:  J C Escolà-Gil; J Julve; A Marzal-Casacuberta; J Ordóñez-Llanos; F González-Sastre; F Blanco-Vaca
Journal:  J Lipid Res       Date:  2000-08       Impact factor: 5.922

9.  Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II.

Authors:  C H Warden; C C Hedrick; J H Qiao; L W Castellani; A J Lusis
Journal:  Science       Date:  1993-07-23       Impact factor: 47.728

Review 10.  Apolipoprotein A-II, HDL metabolism and atherosclerosis.

Authors:  Anne Tailleux; Patrick Duriez; Jean-Charles Fruchart; Véronique Clavey
Journal:  Atherosclerosis       Date:  2002-09       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.